Modality
ERT
MOA
EZH2i
Target
EZH2
Pathway
mTOR
Bladder CaADHD
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
Apr 2017
→ Mar 2031
Phase 3Current
NCT05178352
2,153 pts·ADHD
2025-08→2028-03·Terminated
NCT08576719
732 pts·Bladder Ca
2017-04→2031-03·Recruiting
NCT04768525
1,325 pts·ADHD
2017-07→2025-07·Completed
4,210 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-07-079mo agoPh3 Readout· ADHD
2028-03-222.0y awayPh3 Readout· ADHD
2031-03-175.0y awayPh3 Readout· Bladder Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Recruit…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2025-07-07 · 9mo ago
ADHD
Ph3 Readout
2028-03-22 · 2.0y away
ADHD
Ph3 Readout
2031-03-17 · 5.0y away
Bladder Ca
RecruitingCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05178352 | Phase 3 | ADHD | Terminated | 2153 | 6MWD |
| NCT08576719 | Phase 3 | Bladder Ca | Recruiting | 732 | eGFR |
| NCT04768525 | Phase 3 | ADHD | Completed | 1325 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Tezetapinarof | CG Oncology | Phase 3 | VEGF | |
| NMR-223 | Neumora | NDA/BLA | C5 |